Skip to content

Study · Systematic review · n = 225 · 2017

9 results

Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.

Shomali ME, Ørsted DD, Cannon AJ

Diabetic medicine : a journal of the British Diabetic Association16 Aug 2016Cited by 14 (Europe PMC)

PMID27412701 (opens in a new tab)PMCIDPMC5248619 (opens in a new tab)DOI10.1111/dme.13185 (opens in a new tab)PepBankPUB-27412701
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In African-American people with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c by 11 mmol/mol versus placebo at 26 weeks.

    In plain wordsIn African-American people with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change, liraglutide 1.2 mg
    Study

    n = 225

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · 26 weeksAs given in this study (human).

    Measurements

    HbA1c difference vs placebo
    −11 mmol/mol
    liraglutide 1.2 mg

    Source sentences

    Summary
    In African-American patients (n = 225), HbA1c was significantly reduced at 26 weeks with liraglutide 1.2 and 1.8 mg (-11 and -14 mmol/mol, respectively compared with placebo; P < 0.0001).
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  2. 02HumanSystematic reviewEfficacy outcome

    In African-American people with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c by 14 mmol/mol versus placebo at 26 weeks.

    In plain wordsIn African-American people with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change, liraglutide 1.8 mg
    Study

    n = 225

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    HbA1c difference vs placebo
    −14 mmol/mol
    liraglutide 1.8 mg

    Source sentences

    Summary
    In African-American patients (n = 225), HbA1c was significantly reduced at 26 weeks with liraglutide 1.2 and 1.8 mg (-11 and -14 mmol/mol, respectively compared with placebo; P < 0.0001).
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  3. 03HumanSystematic reviewEfficacy outcome

    In African-American people with type 2 diabetes, liraglutide 1.2 mg lowered fasting plasma glucose by 2.4 mmol/l versus placebo.

    In plain wordsIn African-American people with type 2 diabetes, liraglutide 1.2 mg lowered fasting blood glucose more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose, liraglutide 1.2 mg
    Study

    n = 225

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · 26 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose difference vs placebo
    −2.4 mmol/l
    liraglutide 1.2 mg

    Source sentences

    Summary
    There were also significant reductions in fasting plasma glucose (-2.4 and -3.1 mmol/l, respectively, compared with placebo; P < 0.0001).
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  4. 04HumanSystematic reviewEfficacy outcome

    In African-American people with type 2 diabetes, liraglutide 1.8 mg lowered fasting plasma glucose by 3.1 mmol/l versus placebo.

    In plain wordsIn African-American people with type 2 diabetes, liraglutide 1.8 mg lowered fasting blood glucose more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose, liraglutide 1.8 mg
    Study

    n = 225

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    Fasting plasma glucose difference vs placebo
    −3.1 mmol/l
    liraglutide 1.8 mg

    Source sentences

    Summary
    There were also significant reductions in fasting plasma glucose (-2.4 and -3.1 mmol/l, respectively, compared with placebo; P < 0.0001).
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  5. 05HumanSystematic reviewEfficacy outcome

    In African-American people with type 2 diabetes, liraglutide 1.8 mg reduced body weight by 2.1 kg versus placebo.

    In plain wordsIn African-American people with type 2 diabetes, liraglutide 1.8 mg reduced body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight, liraglutide 1.8 mg
    Study

    n = 225

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    Body weight difference vs placebo
    −2.1 kg
    liraglutide 1.8 mg

    Source sentences

    Summary
    Statistically significant reductions in body weight were observed with 1.8 mg liraglutide (-2.1 kg compared with placebo; P = 0.0056), but not with 1.2 mg liraglutide (-0.26 kg; P = 0.7307).
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  6. 06HumanSystematic reviewEfficacy outcome

    In African-American people with type 2 diabetes, liraglutide 1.2 mg did not significantly change body weight versus placebo.

    In plain wordsIn African-American people with type 2 diabetes, liraglutide 1.2 mg did not significantly change body weight compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight, liraglutide 1.2 mg
    Study

    n = 225

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 mg · 26 weeksAs given in this study (human).

    Measurements

    Body weight difference vs placebo
    −0.26 kg
    liraglutide 1.2 mg

    Source sentences

    Summary
    Statistically significant reductions in body weight were observed with 1.8 mg liraglutide (-2.1 kg compared with placebo; P = 0.0056), but not with 1.2 mg liraglutide (-0.26 kg; P = 0.7307).
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  7. 07HumanSystematic reviewEfficacy outcome

    In people with type 2 diabetes, the treatment-by-race interaction for body weight was significant, so the weight effect of liraglutide differed by race.

    In plain wordsIn people with type 2 diabetes, the weight effect of liraglutide differed between African-American and other patients.

    Peptide
    Liraglutide
    Outcome
    Not applicableTreatment-by-race interaction for body weight
    Study

    n = 225

    Comparator
    Non-African-American patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2-1.8 mg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The P value for interaction between treatment and race was significant for body weight (P = 0.0355).
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  8. 08HumanSystematic reviewSafety outcome

    In African-American people with type 2 diabetes, non-severe hypoglycaemia with liraglutide was low, at 11-15% of patients.

    In plain wordsIn African-American people with type 2 diabetes, 11-15% of patients on liraglutide had non-severe low blood sugar.

    Peptide
    Liraglutide
    Outcome
    Not applicableNon-severe hypoglycaemia incidence
    Study

    n = 225

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.2-1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    Non-severe hypoglycaemia incidence
    11 to 15%
    liraglutide

    Source sentences

    Summary
    The incidence of non-severe hypoglycaemia with liraglutide was low (11-15% of patients), and < 25% of patients receiving liraglutide experienced nausea.
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.
  9. 09HumanSystematic reviewSafety outcome

    In African-American people with type 2 diabetes, fewer than 25% of patients receiving liraglutide experienced nausea.

    In plain wordsIn African-American people with type 2 diabetes, fewer than 25% of patients on liraglutide had nausea.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea incidence
    Study

    n = 225

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.2-1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    < 25%
    liraglutide

    Source sentences

    Summary
    The incidence of non-severe hypoglycaemia with liraglutide was low (11-15% of patients), and < 25% of patients receiving liraglutide experienced nausea.
    2 context sentences
    Summary · context
    Analyses were performed on patient-level data from individuals self-defined as African-American or non-African-American in seven phase III studies.
    Summary · context
    Analyses used data obtained after 26 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.